Introduction to TAK-906
TAK-906, also known as trazpiroben, is a dopamine antagonist drug that was under development for the treatment of gastroparesis. It is a peripherally selective dopamine D2 and D3 receptor antagonist, which makes it a potential therapy for managing the symptoms of gastroparesis, a condition characterized by delayed stomach emptying.
Development History
TAK-906 was originated by Altos Therapeutics and later developed by Takeda Oncology. The drug underwent several clinical trials to assess its efficacy and safety in patients with gastroparesis.
- Clinical Trials: TAK-906 was evaluated in various clinical trials, including Phase 2b studies. For instance, a Phase 2b clinical trial was conducted to assess the efficacy and safety of TAK-906 in adult participants with diabetic gastroparesis[2][4].
- Pharmacokinetics and Safety: Studies were also conducted to evaluate the pharmacokinetics, bioavailability, and drug-drug interaction potential of TAK-906. These studies indicated that TAK-906 did not show significant differences in disposition and safety profile across different ethnic populations[4].
Discontinuation of Development
Despite the promising initial results, the clinical development of TAK-906 was discontinued before April 2022. This decision was likely based on the outcomes of the clinical trials and the overall viability of the drug as a treatment for gastroparesis[1].
Market Projections for Gastroparesis Treatment
Although TAK-906 is no longer in development, the market for gastroparesis treatments continues to grow and evolve.
Market Size and Growth
The global gastroparesis treatment market is expected to exhibit a compound annual growth rate (CAGR) of 3.6% during the forecast period from 2022 to 2030. The market was valued at approximately $8.061 billion in 2022 and is projected to surpass $10.726 billion by 2030[2].
Key Market Trends
- Emerging Therapies: The market is anticipated to be driven by the launch of emerging therapies such as Gimoti (metoclopramide nasal spray), Relamorelin, Tradipitant, Velusetrag, and CIN-102 (deuterated domperidone). These drugs are in late clinical stages of development and are expected to significantly impact the market[5].
- Product Launches: The increasing number of product launches by key market players is expected to drive market growth. For example, EVOKE PHARMA's commercial launch of Gimoti in October 2020 marked a significant milestone in the treatment of acute and recurrent diabetic gastroparesis[2].
Market Segmentation
- Type of Gastroparesis: The idiopathic gastroparesis segment accounted for a major share of the market in 2022. This segment is expected to grow due to the increasing number of clinical trials aimed at addressing the unmet needs of gastroparesis patients[2].
- Route of Administration: The oral segment is estimated to dominate the market, with key players focusing on inorganic growth strategies to expand their product portfolios[2].
Impact of TAK-906 Discontinuation
The discontinuation of TAK-906's development does not significantly impact the overall market growth for gastroparesis treatments, as other promising therapies are advancing through clinical trials and nearing market launch.
"The global gastroparesis treatment market is expected to exhibit a CAGR of 3.6% during the forecast period. A strong focus on research and development by market players to develop innovative products... is likely to create a significant opportunity in the market in the near future."[2]
Conclusion
While TAK-906 is no longer a part of the gastroparesis treatment landscape, the market continues to be driven by innovative therapies and a strong focus on research and development. The discontinuation of TAK-906 highlights the challenges and uncertainties inherent in drug development but does not deter the overall growth and advancement in the treatment of gastroparesis.
Key Takeaways
- TAK-906 Discontinuation: Clinical development of TAK-906 was discontinued before April 2022.
- Market Growth: The global gastroparesis treatment market is expected to grow at a CAGR of 3.6% from 2022 to 2030.
- Emerging Therapies: New therapies like Gimoti, Relamorelin, and others are expected to drive market growth.
- Market Segmentation: Idiopathic gastroparesis and oral administration segments are key drivers of the market.
FAQs
What was TAK-906 intended to treat?
TAK-906 was under development for the treatment of gastroparesis, a condition characterized by delayed stomach emptying.
Why was the development of TAK-906 discontinued?
The development of TAK-906 was discontinued before April 2022, likely due to the outcomes of clinical trials and the overall viability of the drug.
What is the current market size of the gastroparesis treatment market?
The global gastroparesis treatment market was valued at approximately $8.061 billion in 2022.
What is the projected growth rate of the gastroparesis treatment market?
The market is expected to exhibit a CAGR of 3.6% from 2022 to 2030.
Which segment is expected to dominate the gastroparesis treatment market?
The oral segment is estimated to dominate the market in terms of route of administration.
References
- Wikipedia: Trazpiroben
- GlobeNewswire: Global Gastroparesis Treatment Market to Surpass US$10.726 Billion by 2030
- Takeda: Takeda Advances High-Value Late-Stage Pipeline for Growth
- LARVOL DELTA: TAK-906 / Takeda
- BusinessWire: Global Gastroparesis Market Insights, Epidemiology and Forecasts to 2028
